Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension

Guido Grassi, Fosca Quarti-Trevano, Giuseppe Mancia

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The development of angiotensin II receptor blockers (ARB) as a new class of drugs for the management of hypertension has elicited the attention of many clinicians worldwide with the aim of improving blood pressure (BP) control as well as cardiovascular protection.Among ARB telmisartan has been shown to be characterised by an antihypertensive efficacy fully covering the 24-hour period, thereby allowing to antagonise the adverse effects of early morning BP rise on cardiovascular risk. Other specific effects of the drug are represented by its favourable metabolic profile (particularly on insulin sensitivity) and neutral effects on sympathetic cardiovascular function. These properties are coupled with cardioprotective effects, documented by the evidence that the drug: 1) is effective in favouring the regression of cardiac and vascular organ damage, 2) reduces arterial stiffness and improves vascular distensibility and 3) reverses the endothelial dysfunction typical of the hypertensive state particularly when complicated by renal failure, diabetes, obesity or metabolic syndrome. Several of these properties can account for the results of the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), documenting the beneficial effects on the drug on cardiovascular morbidity and mortality.

Original languageEnglish
Pages (from-to)66-74
Number of pages9
JournalJRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Volume9
Issue number2
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Angiotensin Receptor Antagonists
Hypertension
Blood Vessels
Pharmaceutical Preparations
Ramipril
Blood Pressure
Cardiovascular Agents
Vascular Stiffness
Metabolome
Antihypertensive Agents
Renal Insufficiency
Insulin Resistance
Obesity
Morbidity
Mortality
telmisartan

Keywords

  • 24-hour ambulatory blood pressure monitoring
  • Angiotensia II receptor antagonists
  • Blood pressure control
  • Cardiac protection
  • Endothelial function
  • Insulin resistance
  • Left ventricular hypertrophy
  • Traget organ damage
  • Vascular protection

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine

Cite this

Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension. / Grassi, Guido; Quarti-Trevano, Fosca; Mancia, Giuseppe.

In: JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, Vol. 9, No. 2, 06.2008, p. 66-74.

Research output: Contribution to journalArticle

@article{52e7bf9216d5404082a78dac033beb20,
title = "Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension",
abstract = "The development of angiotensin II receptor blockers (ARB) as a new class of drugs for the management of hypertension has elicited the attention of many clinicians worldwide with the aim of improving blood pressure (BP) control as well as cardiovascular protection.Among ARB telmisartan has been shown to be characterised by an antihypertensive efficacy fully covering the 24-hour period, thereby allowing to antagonise the adverse effects of early morning BP rise on cardiovascular risk. Other specific effects of the drug are represented by its favourable metabolic profile (particularly on insulin sensitivity) and neutral effects on sympathetic cardiovascular function. These properties are coupled with cardioprotective effects, documented by the evidence that the drug: 1) is effective in favouring the regression of cardiac and vascular organ damage, 2) reduces arterial stiffness and improves vascular distensibility and 3) reverses the endothelial dysfunction typical of the hypertensive state particularly when complicated by renal failure, diabetes, obesity or metabolic syndrome. Several of these properties can account for the results of the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), documenting the beneficial effects on the drug on cardiovascular morbidity and mortality.",
keywords = "24-hour ambulatory blood pressure monitoring, Angiotensia II receptor antagonists, Blood pressure control, Cardiac protection, Endothelial function, Insulin resistance, Left ventricular hypertrophy, Traget organ damage, Vascular protection",
author = "Guido Grassi and Fosca Quarti-Trevano and Giuseppe Mancia",
year = "2008",
month = "6",
doi = "10.3317/jraas.2008.017",
language = "English",
volume = "9",
pages = "66--74",
journal = "JRAAS - Journal of the Renin-Angiotensin-Aldosterone System",
issn = "1470-3203",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension

AU - Grassi, Guido

AU - Quarti-Trevano, Fosca

AU - Mancia, Giuseppe

PY - 2008/6

Y1 - 2008/6

N2 - The development of angiotensin II receptor blockers (ARB) as a new class of drugs for the management of hypertension has elicited the attention of many clinicians worldwide with the aim of improving blood pressure (BP) control as well as cardiovascular protection.Among ARB telmisartan has been shown to be characterised by an antihypertensive efficacy fully covering the 24-hour period, thereby allowing to antagonise the adverse effects of early morning BP rise on cardiovascular risk. Other specific effects of the drug are represented by its favourable metabolic profile (particularly on insulin sensitivity) and neutral effects on sympathetic cardiovascular function. These properties are coupled with cardioprotective effects, documented by the evidence that the drug: 1) is effective in favouring the regression of cardiac and vascular organ damage, 2) reduces arterial stiffness and improves vascular distensibility and 3) reverses the endothelial dysfunction typical of the hypertensive state particularly when complicated by renal failure, diabetes, obesity or metabolic syndrome. Several of these properties can account for the results of the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), documenting the beneficial effects on the drug on cardiovascular morbidity and mortality.

AB - The development of angiotensin II receptor blockers (ARB) as a new class of drugs for the management of hypertension has elicited the attention of many clinicians worldwide with the aim of improving blood pressure (BP) control as well as cardiovascular protection.Among ARB telmisartan has been shown to be characterised by an antihypertensive efficacy fully covering the 24-hour period, thereby allowing to antagonise the adverse effects of early morning BP rise on cardiovascular risk. Other specific effects of the drug are represented by its favourable metabolic profile (particularly on insulin sensitivity) and neutral effects on sympathetic cardiovascular function. These properties are coupled with cardioprotective effects, documented by the evidence that the drug: 1) is effective in favouring the regression of cardiac and vascular organ damage, 2) reduces arterial stiffness and improves vascular distensibility and 3) reverses the endothelial dysfunction typical of the hypertensive state particularly when complicated by renal failure, diabetes, obesity or metabolic syndrome. Several of these properties can account for the results of the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), documenting the beneficial effects on the drug on cardiovascular morbidity and mortality.

KW - 24-hour ambulatory blood pressure monitoring

KW - Angiotensia II receptor antagonists

KW - Blood pressure control

KW - Cardiac protection

KW - Endothelial function

KW - Insulin resistance

KW - Left ventricular hypertrophy

KW - Traget organ damage

KW - Vascular protection

UR - http://www.scopus.com/inward/record.url?scp=47549101296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47549101296&partnerID=8YFLogxK

U2 - 10.3317/jraas.2008.017

DO - 10.3317/jraas.2008.017

M3 - Article

VL - 9

SP - 66

EP - 74

JO - JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

JF - JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

SN - 1470-3203

IS - 2

ER -